Healthcare Investment Intern - Daan Incubator - National-Level Biopharma & Healthcare Incubator, Subsidiary of Daan Gene - Guangzhou, China
(2026-05 - 2026-08)
- Conducted pre-investment commercial analytics and due diligence on an Alzheimer's blood-based early screening startup, benchmarking 8 domestic and international competitors across clinical need, technology route, regulatory pathway, market access and investment risk; applied TAM/SAM/SOM, top-down patient segmentation and bottom-up hospital/ICL/channel modelling to produce a 56-page investment analysis report with revenue assumptions and a milestone-based recommendation.
- Built scenario-based market sizing and channel uptake assumptions for a mass spectrometry + multi-omics + AI diagnostic solution, translating technical concepts into business implications for IVD registration, pricing, reimbursement, physician adoption, send-out testing feasibility and launch readiness.
- Converted internal insight on China's chronic disease management market into a data-backed "three-highs" distributor and partnership pipeline, segmenting hypertension, hyperglycaemia and hyperlipidaemia opportunities, mapping 6 commercial channel models and screening 13 asset-light third-party distributors through tender records, manufacturer authorisation paths and hospital procurement evidence.
- Supported executive-ready assessment materials for Daan's biopharma and healthcare incubator platform, synthesising portfolio company data, business model, expert network, service capabilities and fund matrix into a full-cycle value creation narrative from early incubation to financing, IPO and M&A exit.
- Contributed to portfolio analytics and monitoring of 57 Daan-invested healthcare companies, tracking litigation, equity changes, management updates and exit-related governance matters; supported on-site due diligence visits and external biotech/medtech innovation events to capture deal-flow and market intelligence signals.
Strategy Consulting Intern - IPSOS Strategy3 - Shanghai, China
(2024-07 - 2025-01)
- Supported a pharmaceutical strategy and business analytics project for a leading Chinese pharma company across R&D pipeline prioritisation, omnichannel commercialisation planning, product lifecycle management and sales force transformation, contributing to client-ready analysis and senior-stakeholder discussions.
- Analysed 150+ R&D projects across oncology, hepatology and respiratory therapeutic areas, evaluating clinical unmet needs, market attractiveness, competitive intensity and me-too vs first-in-class differentiation to build a portfolio prioritisation matrix for resource allocation discussions.
- Conducted market access analytics and patient journey mapping by comparing DTP pharmacy, retail chain and primary care channel economics, assessing innovative vs generic portfolio implications and supporting channel strategy, launch planning and commercial roadmap recommendations.
- Modelled centralised procurement/VBP price erosion and volume scenarios across product categories, quantified revenue exposure by procurement batch and benchmarked competitor positioning to support forecasting assumptions and defensive commercial strategy recommendations.
- Reviewed sales force compliance and performance transformation opportunities by benchmarking peer academic detailing models, evaluating the transition from traditional promotion to compliant customer engagement and supporting a sales effectiveness transformation roadmap.
Team Leader - Pharmaceutical Business Case Competition - Roche Strategy Analysis
(2025-10 - 2025-12)
- Led a university-organised pharmaceutical business case team analysing Roche's drug portfolio, R&D pipeline, therapeutic focus areas and competitive positioning; integrated SAS Enterprise Miner decision tree analysis with strategy research to support market segmentation, growth opportunity assessment and a data-driven final presentation, ultimately shortlisted as finalist.
